The markets opened flat with the Dow adding 3 points to 20,937 as finance and economic ministers from the Group of 20 industrial nations met in Germany. Nasdaq slipped 4 points to 5,896.
On the upside
Bargain hunters lifted shares of Pulmatrix (Nasdaq: PULM).
Caladrius Biosciences (Nasdaq: CLBS) narrowed losses for the fourth quarter as revenue climbed.
Arbutus Biopharma (Nasdaq: ABUS) licensed its proprietary lipid nanoparticle technology to Alexion Pharmaceuticals (Nasdaq: ALXN) for exclusive use in one of Alexion's rare disease programs.
On the downside
Shares of The Medicines Company (Nasdaq: MDCO) plunged ahead of its webcast presentation of data from an ORION-1 Phase II study of inclisiran.
Zosano Pharma (Nasdaq: ZSAN) priced its public offering of 17 million shares of common stock at the discounted price of $1.50 per share.
Esperion Therapeutics (Nasdaq: ESPR) stock plunged after rival Amgen (Nasdaq: AMGN) reported disappointing results for its cholesterol drug Repatha.
In the broad market, advancing issues outpaced decliners by a margin of more than 9 to 7 on the NYSE and by nearly 10 to 9 on Nasdaq. The broader S&P 500 index eased a fraction to 2,380. Bitcoin tumbled $16 to $1,157.